Molecular and cellular basis of lysosomal transmembrane protein dysfunction

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1793, Issue 4, 2009, Pages 636-649

  Ruivo, Raquel ^a   Anne, Christine ^a   Sagné, Corinne ^a   Gasnier, Bruno ^a  

^a INST DE BIOLOGIE PHYSICO CHIMIQUE   (France)

Author keywords

Channel; ClC 7; Cobalamin F type disease; Cystinosin; Cystinosis; Danon disease; HGSNAT; Infantile sialic acid disorder; LAMP2; Lysosomal membrane; Lysosomal storage disorder; Mucolipidosis type IV; Mucolipin; Mucopolysaccharidosis; Osteopetrosis; Ostm1; Salla disease; Sanfilippo C syndrome; Sialin; Transporter; TRPML1

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CALCIUM ION; CATION CHANNEL; COBALAMIN; CYSTINE; CYSTINOSIN; DYNEIN ADENOSINE TRIPHOSPHATASE; FERROUS ION; MEMBRANE PROTEIN; OSTEOPETROSIS ASSOCIATED TRANSMEMBRANE PROTEIN 1; PROTON; SIALIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL MUCOLIPIN 1; UNCLASSIFIED DRUG;

ACIDIFICATION; AUTOPHAGY; CELL FUSION; CELL MOTILITY; CYSTINOSIS; DANON DISEASE; GENE MUTATION; HUMAN; INTRACELLULAR TRANSPORT; ION TRANSPORT; LIFE CYCLE; LIPID STORAGE; LYSOSOME; LYSOSOME MEMBRANE; LYSOSOME STORAGE DISEASE; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; MOLECULAR MECHANICS; NERVE DEGENERATION; NERVE FIBER; NEURONAL CEROID LIPOFUSCINOSIS; NEUROTRANSMISSION; NIEMANN PICK DISEASE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; SANFILIPPO SYNDROME; SIALIC ACID STORAGE DISEASE;

ANIMALS; AUTOPHAGY; BIOLOGICAL TRANSPORT; HUMANS; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; MEMBRANE PROTEINS; PROTEINS;

LACUNA;

EID: 62949241063     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.12.008     Document Type: Review

References (171)

1. Hinton A., Bond S., and Forgac M. V-ATPase functions in normal and disease processes. Pflugers Arch. 457 (2009) 589-598
2. Sagné C., and Gasnier B. Molecular physiology and pathophysiology of lysosomal membrane transporters. J. Inherit. Metab. Dis. 31 (2008) 258-266
3. Luzio J.P., Pryor P.R., and Bright N.A. Lysosomes: fusion and function. Nat. Rev., Mol. Cell Biol. 8 (2007) 622-632
4. Bagshaw R.D., Mahuran D.J., and Callahan J.W. A proteomic analysis of lysosomal integral membrane proteins reveals the diverse composition of the organelle. Mol. Cell. Proteomics 4 (2005) 133-143
5. Schröder B., Wrocklage C., Pan C., Jager R., Kosters B., Schafer H., Elsasser H.P., Mann M., and Hasilik A. Integral and associated lysosomal membrane proteins. Traffic 8 (2007) 1676-1686
6. Fan X., Zhang H., Zhang S., Bagshaw R.D., Tropak M.B., Callahan J.W., and Mahuran D.J. Identification of the gene encoding the enzyme deficient in mucopolysaccharidosis IIIC (Sanfilippo disease type C). Am. J. Hum. Genet. 79 (2006) 738-744
7. Hrebicek M., Mrazova L., Seyrantepe V., Durand S., Roslin N.M., Noskova L., Hartmannova H., Ivanek R., Cizkova A., Poupetova H., Sikora J., Urinovska J., Stranecky V., Zeman J., Lepage P., Roquis D., Verner A., Ausseil J., Beesley C.E., Maire I., Poorthuis B.J., van de Kamp J., van Diggelen O.P., Wevers R.A., Hudson T.J., Fujiwara T.M., Majewski J., Morgan K., Kmoch S., and Pshezhetsky A.V. Mutations in TMEM76* cause mucopolysaccharidosis IIIC (Sanfilippo C syndrome). Am. J. Hum. Genet. 79 (2006) 807-819
8. Ramirez-Montealegre D., and Pearce D.A. Defective lysosomal arginine transport in juvenile Batten disease. Hum. Mol. Genet. 14 (2005) 3759-3773
9. Kim Y., Ramirez-Montealegre D., and Pearce D.A. A role in vacuolar arginine transport for yeast Btn1p and for human CLN3, the protein defective in Batten disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15458-15462
10. Siintola E., Topcu M., Aula N., Lohi H., Minassian B.A., Paterson A.D., Liu X.Q., Wilson C., Lahtinen U., Anttonen A.K., and Lehesjoki A.E. The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. Am. J. Hum. Genet. 81 (2007) 136-146
11. Jalanko A., and Braulke T. Neuronal ceroid lipofuscinoses. Biochim. Biophys. Acta 1793 (2009) 697-709
12. Patterson M.C., Vanier M.T., Suzuki M.C., Moris J.A., Carstea E.D., Neufeld E.B., Blanchette-Mackie E.J., and Pentchev P.G. Niemann-Pick disease type C: a lipid trafficking disorder. In: Scriver C.R., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), MaGraw-Hill, New York 3611-3633
13. Vanier M.T., and Millat G. Niemann-Pick disease type C. Clin. Genet. 64 (2003) 269-281
14. Gahl W.A., Bashan N., Tietze F., Bernardini I., and Schulman J.D. Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science 217 (1982) 1263-1265
15. Jonas A.J., Smith M.L., and Schneider J.A. ATP-dependent lysosomal cystine efflux is defective in cystinosis. J. Biol. Chem. 257 (1982) 13185-13188
16. Gahl W.A., Thoene J.G., and Schneider J.A. Cystinosis. N. Engl. J. Med. 347 (2002) 111-121
17. Town M., Jean G., Cherqui S., Attard M., Forestier L., Whitmore S.A., Callen D.F., Gribouval O., Broyer M., Bates G.P., van't Hoff W., and Antignac C. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat. Genet. 18 (1998) 319-324
18. Cherqui S., Kalatzis V., Trugnan G., and Antignac C. The targeting of cystinosin to the lysosomal membrane requires a tyrosine-based signal and a novel sorting motif. J. Biol. Chem. 276 (2001) 13314-13321
19. Kalatzis V., Cherqui S., Antignac C., and Gasnier B. Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter. EMBO J. 20 (2001) 5940-5949
20. Greene A.A., Marcusson E.G., Morell G.P., and Schneider J.A. Characterization of the lysosomal cystine transport system in mouse L-929 fibroblasts. J. Biol. Chem. 265 (1990) 9888-9895
21. Kalatzis V., Nevo N., Cherqui S., Gasnier B., and Antignac C. Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin. Hum. Mol. Genet. 13 (2004) 1361-1371
22. Taranta A., Petrini S., Palma A., Mannucci L., Wilmer M.J., De Luca V., Diomedi-Camassei F., Corallini S., Bellomo F., van den Heuvel L.P., Levtchenko E.N., and Emma F. Identification and subcellular localization of a new cystinosin isoform. Am. J. Physiol. Renal. Physiol. 294 (2008) F1101-1108
23. Cherqui S., Sevin C., Hamard G., Kalatzis V., Sich M., Pequignot M.O., Gogat K., Abitbol M., Broyer M., Gubler M.C., and Antignac C. Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis. Mol. Cell. Biol. 22 (2002) 7622-7632
24. Baum M. The Fanconi syndrome of cystinosis: insights into the pathophysiology. Pediatr. Nephrol. 12 (1998) 492-497
25. Wilmer M.J., Willems P.H., Verkaart S., Visch H.J., de Graaf-Hess A., Blom H.J., Monnens L.A., van den Heuvel L.P., and Levtchenko E.N. Cystine dimethylester model of cystinosis: still reliable?. Pediatr. Res. 62 (2007) 151-155
26. Christensen E.I., and Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat. Rev., Mol. Cell Biol. 3 (2002) 256-266
27. Wilmer M.J., Christensen E.I., van den Heuvel L.P., Monnens L.A., and Levtchenko E.N. Urinary protein excretion pattern and renal expression of megalin and cubilin in nephropathic cystinosis. Am. J. Kidney Dis. 51 (2008) 893-903
28. Chol M., Nevo N., Cherqui S., Antignac C., and Rustin P. Glutathione precursors replenish decreased glutathione pool in cystinotic cell lines. Biochem. Biophys. Res. Commun. 324 (2004) 231-235
29. Mannucci L., Pastore A., Rizzo C., Piemonte F., Rizzoni G., and Emma F. Impaired activity of the gamma-glutamyl cycle in nephropathic cystinosis fibroblasts. Pediatr. Res. 59 (2006) 332-335
30. Laube G.F., Shah V., Stewart V.C., Hargreaves I.P., Haq M.R., Heales S.J., and van't Hoff W.G. Glutathione depletion and increased apoptosis rate in human cystinotic proximal tubular cells. Pediatr. Nephrol. 21 (2006) 503-509
31. Levtchenko E., de Graaf-Hess A., Wilmer M., van den Heuvel L., Monnens L., and Blom H. Altered status of glutathione and its metabolites in cystinotic cells. Nephrol. Dial. Transplant. 20 (2005) 1828-1832
32. Park M., Helip-Wooley A., and Thoene J. Lysosomal cystine storage augments apoptosis in cultured human fibroblasts and renal tubular epithelial cells. J. Am. Soc. Nephrol. 13 (2002) 2878-2887
33. Park M.A., Pejovic V., Kerisit K.G., Junius S., and Thoene J.G. Increased apoptosis in cystinotic fibroblasts and renal proximal tubule epithelial cells results from cysteinylation of protein kinase Cdelta. J. Am. Soc. Nephrol. 17 (2006) 3167-3175
34. Kroemer G., and Martin S.J. Caspase-independent cell death. Nat. Med. 11 (2005) 725-730
35. Thoene J.G. A review of the role of enhanced apoptosis in the pathophysiology of cystinosis. Mol. Genet. Metab. 92 (2007) 292-298
36. Aula P., and Gahl W.A. Disorders of free sialic acid storage. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 5109-5120
37. Aula N., Salomaki P., Timonen R., Verheijen F., Mancini G., Mansson J.E., Aula P., and Peltonen L. The spectrum of SLC17A5-gene mutations resulting in free sialic acid-storage diseases indicates some genotype-phenotype correlation. Am. J. Hum. Genet. 67 (2000) 832-840
38. Biancheri R., Rossi A., Verbeek H.A., Schot R., Corsolini F., Assereto S., Mancini G.M., Verheijen F.W., Minetti C., and Filocamo M. Homozygosity for the p.K136E mutation in the SLC17A5 gene as cause of an Italian severe Salla disease. Neurogenetics 6 (2005) 195-199
39. Haataja L., Parkkola R., Sonninen P., Vanhanen S.L., Schleutker J., Aarimaa T., Turpeinen U., Renlund M., and Aula P. Phenotypic variation and magnetic resonance imaging (MRI) in Salla disease, a free sialic acid storage disorder. Neuropediatrics 25 (1994) 238-244
40. Parazzini C., Arena S., Marchetti L., Menni F., Filocamo M., Verheijen F.W., Mancini G.M., Triulzi F., and Parini R. Infantile sialic acid storage disease: serial ultrasound and magnetic resonance imaging features. AJNR Am. J. Neuroradiol. 24 (2003) 398-400
41. Sonninen P., Autti T., Varho T., Hamalainen M., and Raininko R. Brain involvement in Salla disease. AJNR Am. J. Neuroradiol. 20 (1999) 433-443
42. Verheijen F.W., Verbeek E., Aula N., Beerens C.E., Havelaar A.C., Joosse M., Peltonen L., Aula P., Galjaard H., van der Spek P.J., and Mancini G.M. A new gene, encoding an anion transporter, is mutated in sialic acid storage diseases. Nat. Genet. 23 (1999) 462-465
43. Fremeau Jr. R.T., Voglmaier S., Seal R.P., and Edwards R.H. VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. Trends Neurosci. 27 (2004) 98-103
44. Tietze F., Seppala R., Renlund M., Hopwood J.J., Harper G.S., Thomas G.H., and Gahl W.A. Defective lysosomal egress of free sialic acid (N-acetylneuraminic acid) in fibroblasts of patients with infantile free sialic acid storage disease. J. Biol. Chem. 264 (1989) 15316-15322
45. Renlund M., Tietze F., and Gahl W.A. Defective sialic acid egress from isolated fibroblast lysosomes of patients with Salla disease. Science 232 (1986) 759-762
46. Mancini G.M., Beerens C.E., Aula P.P., and Verheijen F.W. Sialic acid storage diseases. A multiple lysosomal transport defect for acidic monosaccharides. J. Clin. Invest. 87 (1991) 1329-1335
47. Morin P., Sagné C., and Gasnier B. Functional characterization of wild-type and mutant human sialin. EMBO J. 23 (2004) 4560-4570
48. Wreden C.C., Wlizla M., and Reimer R.J. Varied mechanisms underlie the free sialic acid storage disorders. J. Biol. Chem. 280 (2005) 1408-1416
49. Aula N., Jalanko A., Aula P., and Peltonen L. Unraveling the molecular pathogenesis of free sialic acid storage disorders: altered targeting of mutant sialin. Mol. Genet. Metab. 77 (2002) 99-107
50. Mancini G.M., de Jonge H.R., Galjaard H., and Verheijen F.W. Characterization of a proton-driven carrier for sialic acid in the lysosomal membrane. Evidence for a group-specific transport system for acidic monosaccharides. J. Biol. Chem. 264 (1989) 15247-15254
51. Myall N.J., Wreden C.C., Wlizla M., and Reimer R.J. G328E and G409E sialin missense mutations similarly impair transport activity, but differentially affect trafficking. Mol. Genet. Metab. 92 (2007) 371-374
52. Ruivo R., Sharifi A., Boubekeur S., Morin P., Anne C., Debacker C., Graziano J.C., Sagné C., and Gasnier B. Molecular pathogenesis of sialic acid storage diseases: insight gained from four missense mutations and a putative polymorphism of human sialin. Biol. Cell 100 (2008) 551-559
53. Kleta R., Morse R.P., Orvisky E., Krasnewich D., Alroy J., Ucci A.A., Bernardini I., Wenger D.A., and Gahl W.A. Clinical, biochemical, and molecular diagnosis of a free sialic acid storage disease patient of moderate severity. Mol. Genet. Metab. 82 (2004) 137-143
54. Landau D., Cohen D., Shalev H., Pinsk V., Yerushalmi B., Zeigler M., and Birk O.S. A novel mutation in the SLC17A5 gene causing both severe and mild phenotypes of free sialic acid storage disease in one inbred Bedouin kindred. Mol. Genet. Metab. 82 (2004) 167-172
55. Aula N., Kopra O., Jalanko A., and Peltonen L. Sialin expression in the CNS implicates extralysosomal function in neurons. Neurobiol. Dis. 15 (2004) 251-261
56. Yarovaya N., Schot R., Fodero L., McMahon M., Mahoney A., Williams R., Verbeek E., de Bondt A., Hampson M., van der Spek P., Stubbs A., Masters C.L., Verheijen F.W., Mancini G.M., and Venter D.J. Sialin, an anion transporter defective in sialic acid storage diseases, shows highly variable expression in adult mouse brain, and is developmentally regulated. Neurobiol. Dis. 19 (2005) 351-365
57. Miyaji T., Echigo N., Hiasa M., Senoh S., Omote H., and Moriyama Y. Identification of a vesicular aspartate transporter. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 11720-11724
58. Juge N., Yoshida Y., Yatsushiro S., Omote H., and Moriyama Y. Vesicular glutamate transporter contains two independent transport machineries. J. Biol. Chem. 281 (2006) 39499-39506
59. Mendla K., and Cantz M. Specificity studies on the oligosaccharide neuraminidase of human fibroblasts. Biochem. J. 218 (1984) 625-628
60. Baumkotter J., Cantz M., Mendla K., Baumann W., Friebolin H., Gehler J., and Spranger J. N-Acetylneuraminic acid storage disease. Hum. Genet. 71 (1985) 155-159
61. Pitto M., Chigorno V., Renlund M., and Tettamanti G. Impairment of ganglioside metabolism in cultured fibroblasts from Salla patients. Clin. Chim. Acta 247 (1996) 143-157
62. Sheikh K.A., Sun J., Liu Y., Kawai H., Crawford T.O., Proia R.L., Griffin J.W., and Schnaar R.L. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7532-7537
63. Schachner M., and Bartsch U. Multiple functions of the myelin-associated glycoprotein MAG (siglec-4a) in formation and maintenance of myelin. Glia 29 (2000) 154-165
64. Rosenblatt D.S., Hosack A., Matiaszuk N.V., Cooper B.A., and Laframboise R. Defect in vitamin B12 release from lysosomes: newly described inborn error of vitamin B12 metabolism. Science 228 (1985) 1319-1321
65. Rosenblatt D.S., and Fenton W.A. Inherited disorders of folate and cobalamin transport and metabolism. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 3897-3933
66. Vassiliadis A., Rosenblatt D.S., Cooper B.A., and Bergeron J.J. Lysosomal cobalamin accumulation in fibroblasts from a patient with an inborn error of cobalamin metabolism (cblF complementation group): visualization by electron microscope radioautography. Exp. Cell Res. 195 (1991) 295-302
67. Idriss J.M., and Jonas A.J. Vitamin B12 transport by rat liver lysosomal membrane vesicles. J. Biol. Chem. 266 (1991) 9438-9441
68. Valstar M.J., Ruijter G.J., van Diggelen O.P., Poorthuis B.J., and Wijburg F.A. Sanfilippo syndrome: a mini-review. J. Inherit. Metab. Dis. 31 (2008) 240-252
69. Klein U., Kresse H., and von Figura K. Sanfilippo syndrome type C: deficiency of acetyl-CoA:alpha-glucosaminide N-acetyltransferase in skin fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 5185-5189
70. Bame K.J., and Rome L.H. Acetyl coenzyme A: alpha-glucosaminide N-acetyltransferase. Evidence for a transmembrane acetylation mechanism. J. Biol. Chem. 260 (1985) 11293-11299
71. Rome L.H., Hill D.F., Bame K.J., and Crain L.R. Utilization of exogenously added acetyl coenzyme A by intact isolated lysosomes. J. Biol. Chem. 258 (1983) 3006-3011
72. Bame K.J., and Rome L.H. Acetyl-coenzyme A:alpha-glucosaminide N-acetyltransferase. Evidence for an active site histidine residue. J. Biol. Chem. 261 (1986) 10127-10132
73. Ausseil J., Landry K., Seyrantepe V., Trudel S., Mazur A., Lapointe F., and Pshezhetsky A.V. An acetylated 120-kDa lysosomal transmembrane protein is absent from mucopolysaccharidosis IIIC fibroblasts: a candidate molecule for MPS IIIC. Mol. Genet. Metab. 87 (2006) 22-31
74. Meikle P.J., Whittle A.M., and Hopwood J.J. Human acetyl-coenzyme A:alpha-glucosaminide N-acetyltransferase. Kinetic characterization and mechanistic interpretation. Biochem. J. 308 Pt. 1 (1995) 327-333
75. Bame K.J., and Rome L.H. Genetic evidence for transmembrane acetylation by lysosomes. Science 233 (1986) 1087-1089
76. Del Fattore A., Cappariello A., and Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone 42 (2008) 19-29
77. Steward C.G. Neurological aspects of osteopetrosis. Neuropathol. Appl. Neurobiol. 29 (2003) 87-97
78. Frattini A., Pangrazio A., Susani L., Sobacchi C., Mirolo M., Abinun M., Andolina M., Flanagan A., Horwitz E.M., Mihci E., Notarangelo L.D., Ramenghi U., Teti A., Van Hove J., Vujic D., Young T., Albertini A., Orchard P.J., Vezzoni P., and Villa A. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J. Bone Miner. Res. 18 (2003) 1740-1747
79. Lange P.F., Wartosch L., Jentsch T.J., and Fuhrmann J.C. ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 440 (2006) 220-223
80. Kasper D., Planells-Cases R., Fuhrmann J.C., Scheel O., Zeitz O., Ruether K., Schmitt A., Poet M., Steinfeld R., Schweizer M., Kornak U., and Jentsch T.J. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J. 24 (2005) 1079-1091
81. Pangrazio A., Poliani P.L., Megarbane A., Lefranc G., Lanino E., Di Rocco M., Rucci F., Lucchini F., Ravanini M., Facchetti F., Abinun M., Vezzoni P., Villa A., and Frattini A. Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. J. Bone Miner. Res. 21 (2006) 1098-1105
82. Chalhoub N., Benachenhou N., Rajapurohitam V., Pata M., Ferron M., Frattini A., Villa A., and Vacher J. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat. Med. 9 (2003) 399-406
83. Kornak U., Kasper D., Bosl M.R., Kaiser E., Schweizer M., Schulz A., Friedrich W., Delling G., and Jentsch T.J. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104 (2001) 205-215
84. Cleiren E., Benichou O., Van Hul E., Gram J., Bollerslev J., Singer F.R., Beaverson K., Aledo A., Whyte M.P., Yoneyama T., deVernejoul M.C., and Van Hul W. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum. Mol. Genet. 10 (2001) 2861-2867
85. Jentsch T.J., Poet M., Fuhrmann J.C., and Zdebik A.A. Physiological functions of CLC Cl- channels gleaned from human genetic disease and mouse models. Annu. Rev. Physiol. 67 (2005) 779-807
86. Accardi A., Walden M., Nguitragool W., Jayaram H., Williams C., and Miller C. Separate ion pathways in a Cl-/H+ exchanger. J. Gen. Physiol. 126 (2005) 563-570
87. Graves A.R., Curran P.K., Smith C.L., and Mindell J.A. The Cl-/H+ antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature 453 (2008) 788-792
88. Accardi A., and Miller C. Secondary active transport mediated by a prokaryotic homologue of ClC Cl- channels. Nature 427 (2004) 803-807
89. Picollo A., and Pusch M. Chloride/proton antiporter activity of mammalian CLC proteins ClC-4 and ClC-5. Nature 436 (2005) 420-423
90. Scheel O., Zdebik A.A., Lourdel S., and Jentsch T.J. Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 436 (2005) 424-427
91. De Angeli A., Monachello D., Ephritikhine G., Frachisse J.M., Thomine S., Gambale F., and Barbier-Brygoo H. The nitrate/proton antiporter AtCLCa mediates nitrate accumulation in plant vacuoles. Nature 442 (2006) 939-942
92. Poet M., Kornak U., Schweizer M., Zdebik A.A., Scheel O., Hoelter S., Wurst W., Schmitt A., Fuhrmann J.C., Planells-Cases R., Mole S.E., Hubner C.A., and Jentsch T.J. Lysosomal storage disease upon disruption of the neuronal chloride transport protein ClC-6. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13854-13859
93. Jentsch T.J. Chloride and the endosomal-lysosomal pathway: emerging roles of CLC chloride transporters. J. Physiol. 578 (2007) 633-640
94. Faundez V., and Hartzell H.C. Intracellular chloride channels: determinants of function in the endosomal pathway. Sci. STKE 2004 (2004) re8
95. Goto T., Yamaza T., and Tanaka T. Cathepsins in the osteoclast. J. Electron Microsc. (Tokyo) 52 (2003) 551-558
96. Bach G. Mucolipin 1: endocytosis and cation channel-a review. Pflugers Arch. 451 (2005) 313-317
97. Bach G. Mucolipidosis type IV. Mol. Genet. Metab. 73 (2001) 197-203
98. Sun M., Goldin E., Stahl S., Falardeau J.L., Kennedy J.C., Acierno Jr. J.S., Bove C., Kaneski C.R., Nagle J., Bromley M.C., Colman M., Schiffmann R., and Slaugenhaupt S.A. Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel. Hum. Mol. Genet. 9 (2000) 2471-2478
99. Bassi M.T., Manzoni M., Monti E., Pizzo M.T., Ballabio A., and Borsani G. Cloning of the gene encoding a novel integral membrane protein, mucolipidin-and identification of the two major founder mutations causing mucolipidosis type IV. Am. J. Hum. Genet. 67 (2000) 1110-1120
100. Bargal R., Avidan N., Ben-Asher E., Olender Z., Zeigler M., Frumkin A., Raas-Rothschild A., Glusman G., Lancet D., and Bach G. Identification of the gene causing mucolipidosis type IV. Nat. Genet. 26 (2000) 118-123
101. Venugopal B., Browning M.F., Curcio-Morelli C., Varro A., Michaud N., Nanthakumar N., Walkley S.U., Pickel J., and Slaugenhaupt S.A. Neurologic, gastric, and opthalmologic pathologies in a murine model of mucolipidosis type IV. Am. J. Hum. Genet. 81 (2007) 1070-1083
102. Clapham D.E. TRP channels as cellular sensors. Nature 426 (2003) 517-524
103. Pryor P.R., Reimann F., Gribble F.M., and Luzio J.P. Mucolipin-1 is a lysosomal membrane protein required for intracellular lactosylceramide traffic. Traffic 7 (2006) 1388-1398
104. Vergarajauregui S., and Puertollano R. Two di-leucine motifs regulate trafficking of mucolipin-1 to lysosomes. Traffic 7 (2006) 337-353
105. Owsianik G., Talavera K., Voets T., and Nilius B. Permeation and selectivity of TRP channels. Annu. Rev. Physiol. 68 (2006) 685-717
106. Manzoni M., Monti E., Bresciani R., Bozzato A., Barlati S., Bassi M.T., and Borsani G. Overexpression of wild-type and mutant mucolipin proteins in mammalian cells: effects on the late endocytic compartment organization. FEBS Lett. 567 (2004) 219-224
107. Kiselyov K., Chen J., Rbaibi Y., Oberdick D., Tjon-Kon-Sang S., Shcheynikov N., Muallem S., and Soyombo A. TRP-ML1 is a lysosomal monovalent cation channel that undergoes proteolytic cleavage. J. Biol. Chem. 280 (2005) 43218-43223
108. Chen C.S., Bach G., and Pagano R.E. Abnormal transport along the lysosomal pathway in mucolipidosis, type IV disease. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6373-6378
109. Thompson E.G., Schaheen L., Dang H., and Fares H. Lysosomal trafficking functions of mucolipin-1 in murine macrophages. BMC Cell Biol. 8 (2007) 54
110. Miedel M.T., Rbaibi Y., Guerriero C.J., Colletti G., Weixel K.M., Weisz O.A., and Kiselyov K. Membrane traffic and turnover in TRP-ML1-deficient cells: a revised model for mucolipidosis type IV pathogenesis. J. Exp. Med. 205 (2008) 1477-1490
111. Chen C.S., Patterson M.C., Wheatley C.L., O'Brien J.F., and Pagano R.E. Broad screening test for sphingolipid-storage diseases. Lancet 354 (1999) 901-905
112. Fares H., and Greenwald I. Regulation of endocytosis by CUP-5, the Caenorhabditis elegans mucolipin-1 homolog. Nat. Genet. 28 (2001) 64-68
113. Hersh B.M., Hartwieg E., and Horvitz H.R. The Caenorhabditis elegans mucolipin-like gene cup-5 is essential for viability and regulates lysosomes in multiple cell types. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4355-4360
114. Treusch S., Knuth S., Slaugenhaupt S.A., Goldin E., Grant B.D., and Fares H. Caenorhabditis elegans functional orthologue of human protein h-mucolipin-1 is required for lysosome biogenesis. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4483-4488
115. Schaheen L., Dang H., and Fares H. Basis of lethality in C. elegans lacking CUP-5, the mucolipidosis type IV orthologue. Dev. Biol. 293 (2006) 382-391
116. Schaheen L., Patton G., and Fares H. Suppression of the cup-5 mucolipidosis type IV-related lysosomal dysfunction by the inactivation of an ABC transporter in C. elegans. Development 133 (2006) 3939-3948
117. Jennings Jr. J.J., Zhu J.H., Rbaibi Y., Luo X., Chu C.T., and Kiselyov K. Mitochondrial aberrations in mucolipidosis type IV. J. Biol. Chem. 281 (2006) 39041-39050
118. Eskelinen E.-L., and Saftig P. Autophagy: A lysosomal degradation pathway with a central role in health and disease. Biochim. Biophys. Acta 1793 (2009) 664-673
119. Vergarajauregui S., Connelly P.S., Daniels M.P., and Puertollano R. Autophagic dysfunction in mucolipidosis type IV patients. Hum. Mol. Genet. 17 (2008) 2723-2737
120. Twig G., Elorza A., Molina A.J., Mohamed H., Wikstrom J.D., Walzer G., Stiles L., Haigh S.E., Katz S., Las G., Alroy J., Wu M., Py B.F., Yuan J., Deeney J.T., Corkey B.E., and Shirihai O.S. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 27 (2008) 433-446
121. Venkatachalam K., Long A.A., Elsaesser R., Nikolaeva D., Broadie K., and Montell C. Motor deficit in a Drosophila model of mucolipidosis type IV due to defective clearance of apoptotic cells. Cell 135 (2008) 838-851
122. Cantiello H.F., Montalbetti N., Goldmann W.H., Raychowdhury M.K., Gonzalez-Perrett S., Timpanaro G.A., and Chasan B. Cation channel activity of mucolipin-1: the effect of calcium. Pflugers Arch. 451 (2005) 304-312
123. Raychowdhury M.K., Gonzalez-Perrett S., Montalbetti N., Timpanaro G.A., Chasan B., Goldmann W.H., Stahl S., Cooney A., Goldin E., and Cantiello H.F. Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel. Hum. Mol. Genet. 13 (2004) 617-627
124. LaPlante J.M., Falardeau J., Sun M., Kanazirska M., Brown E.M., Slaugenhaupt S.A., and Vassilev P.M. Identification and characterization of the single channel function of human mucolipin-1 implicated in mucolipidosis type IV, a disorder affecting the lysosomal pathway. FEBS Lett. 532 (2002) 183-187
125. Soyombo A.A., Tjon-Kon-Sang S., Rbaibi Y., Bashllari E., Bisceglia J., Muallem S., and Kiselyov K. TRP-ML1 regulates lysosomal pH and acidic lysosomal lipid hydrolytic activity. J. Biol. Chem. 281 (2006) 7294-7301
126. Xu H., Delling M., Li L., Dong X., and Clapham D.E. Activating mutation in a mucolipin transient receptor potential channel leads to melanocyte loss in varitint-waddler mice. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 18321-18326
127. Dong X.P., Cheng X., Mills E., Delling M., Wang F., Kurz T., and Xu H. The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature 455 (2008) 992-996
128. Miedel M.T., Weixel K.M., Bruns J.R., Traub L.M., and Weisz O.A. Posttranslational cleavage and adaptor protein complex-dependent trafficking of mucolipin-1. J. Biol. Chem. 281 (2006) 12751-12759
129. Zeevi D.A., Frumkin A., and Bach G. TRPML and lysosomal function. Biochim. Biophys. Acta 1772 (2007) 851-858
130. Venkatachalam K., Hofmann T., and Montell C. Lysosomal localization of TRPML3 depends on TRPML2 and the mucolipidosis-associated protein TRPML1. J. Biol. Chem. 281 (2006) 17517-17527
131. Kim H.J., Li Q., Tjon-Kon-Sang S., So I., Kiselyov K., Soyombo A.A., and Muallem S. A novel mode of TRPML3 regulation by extracytosolic pH absent in the varitint-waddler phenotype. EMBO J. 27 (2008) 1197-1205
132. Nagata K., Zheng L., Madathany T., Castiglioni A.J., Bartles J.R., and Garcia-Anoveros J. The varitint-waddler (Va) deafness mutation in TRPML3 generates constitutive, inward rectifying currents and causes cell degeneration. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 353-358
133. Grimm C., Cuajungco M.P., van Aken A.F., Schnee M., Jors S., Kros C.J., Ricci A.J., and Heller S. A helix-breaking mutation in TRPML3 leads to constitutive activity underlying deafness in the varitint-waddler mouse. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19583-19588
134. Kim H.J., Li Q., Tjon-Kon-Sang S., So I., Kiselyov K., and Muallem S. Gain-of-function mutation in TRPML3 causes the mouse varitint-waddler phenotype. J. Biol. Chem. 282 (2007) 36138-36142
135. Atiba-Davies M., and Noben-Trauth K. TRPML3 and hearing loss in the varitint-waddler mouse. Biochim. Biophys. Acta 1772 (2007) 1028-1031
136. Piper R.C., and Luzio J.P. CUPpling calcium to lysosomal biogenesis. Trends Cell Biol. 14 (2004) 471-473
137. Brauchi S., Krapivinsky G., Krapivinsky L., and Clapham D.E. TRPM7 facilitates cholinergic vesicle fusion with the plasma membrane. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 8304-8308
138. Bach G., Chen C.S., and Pagano R.E. Elevated lysosomal pH in mucolipidosis type IV cells. Clin. Chim. Acta 280 (1999) 173-179
139. Danon M.J., Carpenter S., Manaligod J.R., and Schliselfeld L.H. Fatal infantile glycogen storage disease: deficiency of phosphofructokinase and phosphorylase b kinase. Neurology 31 (1981) 1303-1307
140. Malicdan M.C., Noguchi S., Nonaka I., Saftig P., and Nishino I. Lysosomal myopathies: an excessive build-up in autophagosomes is too much to handle. Neuromuscul. Disord. 18 (2008) 521-529
141. Nishino I., Fu J., Tanji K., Yamada T., Shimojo S., Koori T., Mora M., Riggs J.E., Oh S.J., Koga Y., Sue C.M., Yamamoto A., Murakami N., Shanske S., Byrne E., Bonilla E., Nonaka I., DiMauro S., and Hirano M. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406 (2000) 906-910
142. Sugie K., Koori T., Yamamoto A., Ogawa M., Hirano M., Inoue K., Nonaka I., and Nishino I. Characterization of Danon disease in a male patient and his affected mother. Neuromuscul. Disord. 13 (2003) 708-711
143. Tanaka Y., Guhde G., Suter A., Eskelinen E.L., Hartmann D., Lullmann-Rauch R., Janssen P.M., Blanz J., von Figura K., and Saftig P. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 406 (2000) 902-906
144. Eskelinen E.L., Illert A.L., Tanaka Y., Schwarzmann G., Blanz J., Von Figura K., and Saftig P. Role of LAMP-2 in lysosome biogenesis and autophagy. Mol. Biol. Cell 13 (2002) 3355-3368
145. Andrejewski N., Punnonen E.L., Guhde G., Tanaka Y., Lullmann-Rauch R., Hartmann D., von Figura K., and Saftig P. Normal lysosomal morphology and function in LAMP-1-deficient mice. J. Biol. Chem. 274 (1999) 12692-12701
146. Eskelinen E.L., Schmidt C.K., Neu S., Willenborg M., Fuertes G., Salvador N., Tanaka Y., Lullmann-Rauch R., Hartmann D., Heeren J., von Figura K., Knecht E., and Saftig P. Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts. Mol. Biol. Cell 15 (2004) 3132-3145
147. Massey A.C., Zhang C., and Cuervo A.M. Chaperone-mediated autophagy in aging and disease. Curr. Top. Dev. Biol. 73 (2006) 205-235
148. Cuervo A.M., and Dice J.F. A receptor for the selective uptake and degradation of proteins by lysosomes. Science 273 (1996) 501-503
149. Zhou D., Li P., Lin Y., Lott J.M., Hislop A.D., Canaday D.H., Brutkiewicz R.R., and Blum J.S. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity 22 (2005) 571-581
150. Binker M.G., Cosen-Binker L.I., Terebiznik M.R., Mallo G.V., McCaw S.E., Eskelinen E.L., Willenborg M., Brumell J.H., Saftig P., Grinstein S., and Gray-Owen S.D. Arrested maturation of Neisseria-containing phagosomes in the absence of the lysosome-associated membrane proteins, LAMP-1 and LAMP-2. Cell. Microbiol. 9 (2007) 2153-2166
151. Huynh K.K., Eskelinen E.L., Scott C.C., Malevanets A., Saftig P., and Grinstein S. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 26 (2007) 313-324
152. Beertsen W., Willenborg M., Everts V., Zirogianni A., Podschun R., Schröder B., Eskelinen E.L., and Saftig P. Impaired phagosomal maturation in neutrophils leads to periodontitis in lysosomal-associated membrane protein-2 knockout mice. J. Immunol. 180 (2008) 475-482
153. Gonzalez-Polo R.A., Boya P., Pauleau A.L., Jalil A., Larochette N., Souquere S., Eskelinen E.L., Pierron G., Saftig P., and Kroemer G. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J. Cell. Sci. 118 (2005) 3091-3102
154. Jahreiss L., Menzies F.M., and Rubinsztein D.C. The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. Traffic 9 (2008) 574-587
155. Gao X.D., Wang J., Keppler-Ross S., and Dean N. ERS1 encodes a functional homologue of the human lysosomal cystine transporter. FEBS J. 272 (2005) 2497-2511
156. Consortium, Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium, Cell 82 (1995) 949-957.
157. Cotman S.L., Vrbanac V., Lebel L.A., Lee R.L., Johnson K.A., Donahue L.R., Teed A.M., Antonellis K., Bronson R.T., Lerner T.J., and MacDonald M.E. Cln3(Deltaex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum. Mol. Genet. 11 (2002) 2709-2721
158. Eliason S.L., Stein C.S., Mao Q., Tecedor L., Ding S.L., Gaines D.M., and Davidson B.L. A knock-in reporter model of Batten disease. J. Neurosci. 27 (2007) 9826-9834
159. Mitchison H.M., Bernard D.J., Greene N.D., Cooper J.D., Junaid M.A., Pullarkat R.K., de Vos N., Breuning M.H., Owens J.W., Mobley W.C., Gardiner R.M., Lake B.D., Taschner P.E., and Nussbaum R.L. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The batten mouse model consortium [corrected]. Neurobiol. Dis. 6 (1999) 321-334
160. Pearce D.A., and Sherman F. A yeast model for the study of Batten disease. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6915-6918
161. Gachet Y., Codlin S., Hyams J.S., and Mole S.E. btn1, the Schizosaccharomyces pombe homologue of the human Batten disease gene CLN3, regulates vacuole homeostasis. J. Cell. Sci. 118 (2005) 5525-5536
162. Carstea E.D., Morris J.A., Coleman K.G., Loftus S.K., Zhang D., Cummings C., Gu J., Rosenfeld M.A., Pavan W.J., Krizman D.B., Nagle J., Polymeropoulos M.H., Sturley S.L., Ioannou Y.A., Higgins M.E., Comly M., Cooney A., Brown A., Kaneski C.R., Blanchette-Mackie E.J., Dwyer N.K., Neufeld E.B., Chang T.Y., Liscum L., Strauss III J.F., Ohno K., Zeigler M., Carmi R., Sokol J., Markie D., O'Neill R.R., van Diggelen O.P., Elleder M., Patterson M.C., Brady R.O., Vanier M.T., Pentchev P.G., and Tagle D.A. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277 (1997) 228-231
163. Ohgami N., Ko D.C., Thomas M., Scott M.P., Chang C.C., and Chang T.Y. Binding between the Niemann-Pick C1 protein and a photoactivatable cholesterol analog requires a functional sterol-sensing domain. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 12473-12478
164. Infante R.E., Abi-Mosleh L., Radhakrishnan A., Dale J.D., Brown M.S., and Goldstein J.L. Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein. J. Biol. Chem. 283 (2008) 1052-1063
165. Loftus S.K., Morris J.A., Carstea E.D., Gu J.Z., Cummings C., Brown A., Ellison J., Ohno K., Rosenfeld M.A., Tagle D.A., Pentchev P.G., and Pavan W.J. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 277 (1997) 232-235
166. Somers K.L., Royals M.A., Carstea E.D., Rafi M.A., Wenger D.A., and Thrall M.A. Mutation analysis of feline Niemann-Pick C1 disease. Mol. Genet. Metab. 79 (2003) 99-103
167. Phillips S.E., Woodruff III E.A., Liang P., Patten M., and Broadie K. Neuronal loss of Drosophila NPC1a causes cholesterol aggregation and age-progressive neurodegeneration. J. Neurosci. 28 (2008) 6569-6582
168. Sym M., Basson M., and Johnson C. A model for Niemann-Pick type C disease in the nematode Caenorhabditis elegans. Curr. Biol. 10 (2000) 527-530
169. Berger A.C., Hanson P.K., Wylie Nichols J., and Corbett A.H. A yeast model system for functional analysis of the Niemann-Pick type C protein 1 homolog, Ncr1p. Traffic 6 (2005) 907-917
170. Dutzler R., Campbell E.B., Cadene M., Chait B.T., and MacKinnon R. X-ray structure of a ClC chloride channel at 3.0 A reveals the molecular basis of anion selectivity. Nature 415 (2002) 287-294
171. F. Rutsch, S. Gailus, I.R. Miousse, T. Suormala, C. Sagné, M.R. Toliat, G. Nurnberg, T. Wittkampf, I. Buers, A. Sharifi, M. Stucki, C. Becker, M. Baumgartner, H. Robenek, T. Marquardt, W. Hohne, B. Gasnier, D.S. Rosenblatt, B. Fowler, P. Nurnberg, Identification of a putative lysosomal cobalamin exporter altered in the cblF defect of vitamin B(12) metabolism, Nat. Genet. Advance online publication, 11 January 2009; doi:10.1038/ng.294.